Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

The New York Times, a bastion of censorship and corruption, warns the world that “America Has a Free Speech Problem.”

By Tony Lyons, President, Skyhorse Publishing

In a bold but clearly disingenuous statement from its famed Editorial Board, “a group of opinion journalists whose views are informed by expertise, research, debate, and certain longstanding values,” the New York Times issued a cautionary statement:

“For all the tolerance and enlightenment that modern society claims, Americans are losing hold of a fundamental right as citizens of a free country: the right to speak their minds and voice their opinions in public without fear of being shamed or shunned.”

The Editorial Board pounded the point home:

“People should be able to put forward viewpoints, ask questions and make mistakes, and take unpopular but good-faith positions on issues that society is still working through—all without fearing cancellation…Freedom of speech requires not just a commitment to openness and tolerance in the abstract. It demands conscientiousness…We believe it isn’t enough for Americans to just believe in the rights of others to speak freely; they should also find ways to actively support and protect those rights.”

.

.

.

“Despite all the lying, or maybe in reaction to it,” Tucker Carlson wrote, “Robert F. Kennedy Jr. is becoming a legitimate folk hero.”

He is a folk hero because he stood up, grabbed a bullhorn, and spoke truth to power. He’s risked everything and lost a lot. He’s realized that you either care about justice or you care about personal consequences. And for him there have been many.

After suppressing freedom of speech for two years, after defending a specific, myopic and harmful narrative, the Editorial Board of the New York Times decided it was the perfect time to take a strong stance against censorship and cancel culture.

The irony of the most powerful and impactful violator of First Amendment rights lamenting the lack of free speech and offering up ideas to protect the rights of Americans was palpable, inescapable, and despicable.

https://rwmalonemd.substack.com/p/mendacious-new-york-times-warning

American Conversations Hosts Christine Dolan and L Todd Wood speak with Tony Lyons of Skyhorse Publishing and medical freedom activist Sofia Karstens who tell the story behind Robert F Kennedy's book 'The Real Anthony Fauci'.

https://rumble.com/vuoh41-episode-3-the-authors-the-story-behind-robert-f-kennedys-book-the-real-anth.html

“Aviptadil is a drug that mimics vasoactive intestinal polypeptide (VIP), however, with prolonged effects, compared to the endogenous (produced by the body) VIP,” he said.

“VIP and aviptadil act in a type of lung cell called alveolar type II (AT-2), that, although representing just as few as 5% of the cells in the lungs, are largely responsible for oxygen transfer and inhibition of dysfunctional hyper inflammatory reaction and cytokine storm, through the inhibition of the activity of one of the main triggers of these reactions, called NMDA-induced caspase-3.”

Dr. Cadegiani noted that “to date, there is no other molecule capable of working at late stage against COVID-19, and at the same not causing immunosuppression.”

He also believes aviptadil blocks the IL-6, the most dangerous cytokine at the center of the pulmonary dysfunction related to COVID-19. “The importance is that IL-6 is the cytokine that is not effectively blocked by glucocorticoids, even in very high doses. Thus, aviptadil/VIP could confer additional protection when we most need and when we have the fewest resources for.”

He went further to suggest that it is downright malpractice for hospitals not to try this drug at late stage, given the absence of alternatives. “Due to the absence of therapeutic alternatives targeting AT-2 and IL-6, and given the already well-established safety profile, its approval goes beyond the attempt-to-try principle, since it is highly plausible and likely that it works. Therefore, instead of an action of attempt-to-try when giving aviptadil, not providing it when patients fail to respond to other therapies can be considered a medical negligence, from a bioethical perspective.”

https://amgreatness.com/2022/03/09/in-letter-to-fda-and-niaid-ron-johnson-demands-to-know-why-promising-late-stage-covid-drug-was-never-approved/

Vaccine: Micro Blood Clots in D-dimer tests??

https://rumble.com/vv70q7-emergency-medicine-doctor-shows-micro-blood-clots-in-d-dimer-tests.html